Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.94 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.94 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.62 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.54 |
| ▸ | CACNA1B known ✓ | Q00975 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.94 |
| ▸ | HPGD | P15428 | 3/20 | 0.94 |
| ▸ | NQO2 | P16083 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acridine SCHEMBL30257128 | 1.00 | MAPT (0.94) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL1798660 | 1.00 | MAPT (0.94) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL28062881 | 0.97 | MAPT (0.88) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL4972293 | 0.97 | ALDH1A1 (1.00) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL3045498 | 0.97 | ALDH1A1 (1.00) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL8339 | 0.97 | ALDH1A1 (1.00) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL1772714 | 0.97 | ALDH1A1 (1.00) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL29352289 | 0.97 | ALDH1A1 (1.00) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL1551975 | 0.94 | ALDH1A1 (0.94) | MAPTALDH1A1HPGDGLAACHE | |
| Acridine SCHEMBL2401648 | 0.94 | ALDH1A1 (0.94) | MAPTALDH1A1HPGDGLAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139331-A1 | HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS | PIVOT BIO INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20220282340-A1 | HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS | HSBC BANK USA, N.A. | 2022-09-08 | — | — | US | claimed |
| CN-114008221-A | High throughput method for isolating and characterizing pools of ammonium secreting mutants generated by chemical mutagenesis | 皮沃特生物股份有限公司 | 2022-02-01 | — | — | CN | claimed |
| WO-1999006405-A1 | PYRAZOLO-ACRIDINE DERIVATIVES HAVING ANTITUMOUR ACTIVITY | UNIVERSITA' DEGLI STUDI DI CAMERINO (IT) | 1999-02-11 | — | — | WO | claimed |
| US-20260139331-A1 | HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS | PIVOT BIO INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12612669-B2 | High-throughput methods for isolating and characterizing ammonium-excreting mutant libraries generated by chemical mutagenesis | PIVOT BIO, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12442014-B2 | Oomycete resistance in cucumber and tomato | NUNHEMS B.V. (NL) | 2025-10-14 | — | — | US | disclosed |
| CN-113924367-B | Method for improving rice grain yield | 南京农业大学 | 2024-07-23 | — | — | CN | disclosed |
| US-11987799-B2 | Downy mildew resistance in Cucurbitaceae plants | NUNHEMS B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| CN-115918526-A | Haploid inducer compositions and methods of use thereof | 先正达参股股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115915927-A | Methods for inducing endogenous tandem replication events | 莱顿大学医学中心附属莱顿教学医院 | 2023-04-04 | — | — | CN | disclosed |
| US-20220282340-A1 | HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS | HSBC BANK USA, N.A. | 2022-09-08 | — | — | US | disclosed |
| EP-2426205-A1 | GENES HOMOLOGOUS TO THE FLOWERING LOCUS T (FT) GENE AND THE USE THEREOF FOR MODULATING TUBERIZATION | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-03-07 | — | — | EP | disclosed |
| CN-1942430-A | 5-aminolevulinic acid salts, method for the production thereof and use thereof | COSMO OIL CO LTD (JP) | 2007-04-04 | — | — | CN | disclosed |
| CN-1163595-C | Process for inactivation of viruses with aid of acridine or acridine derivatives | — | 2004-08-25 | — | — | CN | disclosed |
| US-5871361-A | Educational kit | MICROBIX BIOSYSTEMS, INC. (CA) | 1999-02-16 | — | — | US | disclosed |
| WO-1999006405-A1 | PYRAZOLO-ACRIDINE DERIVATIVES HAVING ANTITUMOUR ACTIVITY | UNIVERSITA' DEGLI STUDI DI CAMERINO (IT) | 1999-02-11 | — | — | WO | disclosed |
| CN-1132249-A | Process for inactivation of viruses with aid of acridine or acridine derivatives | BEHRINGWERKE AG (DE) | 1996-10-02 | — | — | CN | disclosed |
| US-4244954-A | Acridine compounds and methods of combatting viruses with them | STERLING DRUG INC. (US) | 1981-01-13 | — | — | US | disclosed |
| US-4150134-A | Aminoalkoxy substituted 9(aryl or aralkyl)-acridines | STERLING DRUG INC. (US) | 1979-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612669-B2 | High-throughput methods for isolating and characterizing ammonium-excreting mutant libraries generated by chemical mutagenesis | QPCTL, GLUL, GFPT1 | GLA 2655/4885ACHE 4139/4885HTR3A 4412/4885 |
| US-20260139331-A1 | HIGH-THROUGHPUT METHODS FOR ISOLATING AND CHARACTERIZING AMMONIUM-EXCRETING MUTANT LIBRARIES GENERATED BY CHEMICAL MUTAGENESIS | GLUL, SPOUT1, QPCTL | GLA 2376/4885ACHE 3542/4885HTR3A 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.